Eur Urol:科学家在具有前列腺癌家族史和侵袭性前列腺癌患者中鉴定了10个与前列腺癌风险相关的新基因

2020-09-10 AlexYang MedSci原创

众所周知,家族史是前列腺癌的一个危险因素,常见和罕见的基因变异都与该疾病有关。最近一项发表在Eur Urol期刊的研究中,来自美国梅奥诊所、澳大利亚墨尔本大学、德国乌尔姆大学等多国机构的研究人员利用家

众所周知,家族史是前列腺癌的一个危险因素,常见和罕见的基因变异都与该疾病有关。最近一项发表在Eur Urol期刊的研究中,来自美国梅奥诊所、澳大利亚墨尔本大学、德国乌尔姆大学等多国机构的研究人员利用家族史和更具有侵袭性的前列腺癌数据,探索了与前列腺癌相关的新基因变异。

研究人员进行了两阶段的实验。在第一阶段,他们使用全外显子组测序在具有强烈家族史或更具有侵袭性疾病的患病男性中鉴定了潜在风险等位基因(491例病例和429例对照)。侵袭性疾病是基于Gleason评分、淋巴结状况、转移、肿瘤分期、诊断时前列腺特异性抗原、全身复发和前列腺癌死亡时间综合判定的。第一阶段鉴定出基因后,在第二阶段进行筛选,研究人员采用自定义捕获设计,对2917个独立病例和1899个对照病例进行筛选。随后,他们比较了病例和对照组之间的遗传变异频率。

他们共检测到11个先前报道的与PCa相关的基因(ATM、BRCA2、HOXB13、FAM111A、EMSY、HNF1B、KLK3、MSMB、PCAT1、PRSS3、TERT),以及另外10个新基因(PABPC1、QK1、FAM114A1、MUC6、MYCBP2、RAPGEF4、RNASEH2B、ULK4、XPO7、THAP3)。在这10个新基因中,除了PABPC1和ULK4外,其他基因都与侵袭性PCa风险相关。

该研究证明了基因测序在寻找与PCa相关的基因变异方面的优势,以及从具有强烈的疾病家族史或侵袭性疾病的患者中抽取样本的意义。并证明在有强烈前列腺癌家族史的男性或有侵袭性前列腺癌的男性中有多个基因与该疾病相关。

原始出处:

Daniel J Schaid, Shannon K McDonnell, Liesel M FitzGerald et al. Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. Eur Urol. August 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
    2020-09-11 穿越地平线

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
    2020-09-12 sunyl07
  5. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
    2020-09-10 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2061959, encodeId=3d9720619594a, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Thu Jan 21 21:48:29 CST 2021, time=2021-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2022588, encodeId=59782022588dd, content=<a href='/topic/show?id=42b532553af' target=_blank style='color:#2F92EE;'>#前列腺癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32553, encryptionId=42b532553af, topicName=前列腺癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Wed Dec 23 10:48:29 CST 2020, time=2020-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884621, encodeId=0e07884621e0, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=33015413550, createdName=穿越地平线, createdTime=Fri Sep 11 21:16:38 CST 2020, time=2020-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366374, encodeId=807c13663e4ca, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479813, encodeId=f79314e981315, content=<a href='/topic/show?id=fe7e4641ed7' target=_blank style='color:#2F92EE;'>#家族史#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46417, encryptionId=fe7e4641ed7, topicName=家族史)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f367584357, createdName=396094184_42047357, createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616384, encodeId=5bc71616384c2, content=<a href='/topic/show?id=0d9658313ea' target=_blank style='color:#2F92EE;'>#新基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58313, encryptionId=0d9658313ea, topicName=新基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7919746090, createdName=12498b3em14(暂无昵称), createdTime=Sat Sep 12 11:48:29 CST 2020, time=2020-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040831, encodeId=11fb10408311c, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Sep 10 23:48:29 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884325, encodeId=70b888432596, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Thu Sep 10 21:23:14 CST 2020, time=2020-09-10, status=1, ipAttribution=)]
    2020-09-10 wxl882001

    了解

    0

相关资讯

Prostate Cancer P D:高风险前列腺癌患者中的神经血管束保留与肿瘤结果相关性分析

最近,有研究人员调查了高风险和/或局部晚期前列腺癌(PCa)患者中进行根治性前列腺切除术时保留神经血管束(NVB)的肿瘤安全性情况。

Cell Death Dis:PLCɛ对前列腺癌中AR信号的功能维持至关重要

前列腺癌(CaP)作为男性最常见的恶性肿瘤之一,在美国的估计新发病例中排名第一,癌症相关死亡中排名第三。雄激素受体(AR)信号通路在CaP的发生发展中起着至关重要的作用。AR信号的过度激活会促进细胞增

Nat Commun:DOT1L调控前列腺癌中AR和MYC的稳定性

组蛋白甲基转移酶目前已成为肿瘤学中的一个重要治疗靶标,但其在多种恶性肿瘤发病机制中的作用还知之甚少。DOT1L是一种组蛋白甲基转移酶,可甲基化组蛋白H32的第79位赖氨酸。H3K79甲基化主要与转录激

Molecular Cell:DNA损伤促进TMPRSS2-ERG癌蛋白降解并抑制前列腺癌进展

前列腺癌(PCa)作为男性中最常被诊断出的癌症,其是西方国家男性的癌症相关死亡中的第二大主因。目前局部PCa的治疗方法包括手术和放疗,而雄激素剥夺疗法(ADT)是晚期PCa的主要治疗手段。

Prostate Cancer P D:两种消融技术治疗放射复发前列腺癌的长期结果

前列腺癌放疗后复发的男性,进一步治疗仍旧是一个挑战。常规的雄激素剥夺疗法(ADT)挽救方案有不良影响。另外,只有选择的部分男性可以进行挽救性治疗。最近,有研究人员阐释了两种全腺消融技术-冷冻疗法(sC

Nat Commun:前列腺癌中组蛋白甲基转移酶DOT1L能够协调AR和MYC的稳定性

组蛋白甲基转移酶DOT1L能够甲基化组蛋白H3上的赖氨酸79(K79),并与混合系白血病(MLL)融合白血病的发生有关;然而,DOT1L在前列腺癌(PCa)中的作用尚未确定。